OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ovid Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.17+0.02 (+0.93%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ovid Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License and other revenue | – | – | – | – | – | – | – | $1.50M | $1.46M | $1.45M | $1.45M | $12.38M | – | – |
| Related Party | – | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $196.00M | – | – |
By region
From the segment and revenue-disaggregation notes of Ovid Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.